VOR BIOPHARMA INC(NASDAQ:VOR) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to VOR. VOR was compared to 563 industry peers in the Biotechnology industry. The financial health of VOR is average, but there are quite some concerns on its profitability. VOR has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

VOR had negative earnings in the past year.

In the past year VOR has reported a negative cash flow from operations.

In the past 5 years VOR always reported negative net income.

VOR had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -81.82%, VOR is doing worse than 69.98% of the companies in the same industry.

VOR has a Return On Equity (-120.95%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-81.82%
ROE	-120.95%
ROIC	N/A

ROA(3y)-57.36%

ROA(5y)-53.18%

ROE(3y)-78.63%

ROE(5y)-74.06%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VOR so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

VOR has more shares outstanding than it did 1 year ago.

VOR has more shares outstanding than it did 5 years ago.

VOR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -6.36, we must say that VOR is in the distress zone and has some risk of bankruptcy.

VOR has a worse Altman-Z score (-6.36) than 65.36% of its industry peers.

VOR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-6.36

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 5.19 indicates that VOR has no problem at all paying its short term obligations.

VOR has a Current ratio (5.19) which is comparable to the rest of the industry.

VOR has a Quick Ratio of 5.19. This indicates that VOR is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 5.19, VOR is in line with its industry, outperforming 57.73% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	5.19
Quick Ratio	5.19

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

VOR shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.41%.

EPS 1Y (TTM)3.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-12.82%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, VOR will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.78% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y46.48%

EPS Next 2Y22.31%

EPS Next 3Y13.68%

EPS Next 5Y18.78%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VOR. In the last year negative earnings were reported.

Also next year VOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

VOR's earnings are expected to grow with 13.68% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y22.31%

EPS Next 3Y13.68%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

VOR does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VOR BIOPHARMA INC

NASDAQ:VOR (5/9/2025, 5:52:10 PM)

After market: 0.1531 +0 (+1.19%)

0.1513

-0.01 (-5.44%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-07 2025-05-07/amc

Earnings (Next)08-06 2025-08-06/amc

Inst Owners49.54%

Inst Owner Change0.01%

Ins Owners0.74%

Ins Owner Change95.97%

Market Cap18.89M

Analysts87.27

Price Target9.03 (5868.27%)

Short Float %1.55%

Short Ratio4.7

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-25.51%

Min EPS beat(2)-52.48%

Max EPS beat(2)1.46%

EPS beat(4)2

Avg EPS beat(4)-16.47%

Min EPS beat(4)-52.48%

Max EPS beat(4)2.83%

EPS beat(8)3

Avg EPS beat(8)-7.54%

EPS beat(12)5

Avg EPS beat(12)-4.45%

EPS beat(16)8

Avg EPS beat(16)-1.37%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-24.85%

PT rev (3m)-24.85%

EPS NQ rev (1m)4.36%

EPS NQ rev (3m)5.64%

EPS NY rev (1m)8.56%

EPS NY rev (3m)17.57%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.2
P/tB	0.2
EV/EBITDA	N/A

EPS(TTM)-1.7

EYN/A

EPS(NY)-0.91

Fwd EYN/A

FCF(TTM)-0.8

FCFYN/A

OCF(TTM)-0.8

OCFYN/A

SpS0

BVpS0.77

TBVpS0.77

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-81.82%
ROE	-120.95%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-57.36%

ROA(5y)-53.18%

ROE(3y)-78.63%

ROE(5y)-74.06%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	6.49%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.19
Quick Ratio	5.19
Altman-Z	-6.36

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)123.83%

Cap/Depr(5y)265.1%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)3.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-12.82%

EPS Next Y46.48%

EPS Next 2Y22.31%

EPS Next 3Y13.68%

EPS Next 5Y18.78%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y3.85%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-5.68%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y1.45%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y0.63%

OCF growth 3YN/A

OCF growth 5YN/A

VOR BIOPHARMA INC (VOR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens